US EditionPfizer scraps daily weight loss pill after liver injury in one patient
- Pfizer has decided to discontinue the development of its daily obesity pill, danuglipron, following a liver injury in a trial participant, which resolved after they stopped taking the drug.
- Despite the setback, Pfizer continues to pursue other obesity treatments and focuses on its oral GIPR antagonist candidate.
- Pfizer's Chief Scientific Officer stated they are committed to pursuing promising programs despite the setback.
- Pfizer has also abandoned a twice-daily version of danuglipron and will cease testing it in combination with other obesity drugs.
131 Articles
131 Articles
A generation of women are still haunted by WeightWatchers
So long, WeightWatchers – it’s time to step on the scale for the last time. The much-maligned weight loss company is getting ready to file for bankruptcy, according to reports. Insiders have cited the twin pressures of long-running financial woes and the rise of weight loss drugs as the reasons for its looming demise. I won’t miss it. Those of us who grew up in the “nothing tastes as good as skinny feels” noughties grew up in the long shadow of …
Watauga Democrat
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury
Key Takeaways
Pfizer Pulls Plug On Weight Loss Pill Amid Liver Damage Fears
Pfizer announced it is ending its development of its experimental oral GLP-1 drug to treat obesity, the company said on Monday, after a patient in a trial suffered a liver injury potentially caused by the experimental drug known as danuglipron.
PBS NewsHour
UpstractPfizer abandons potential obesity treatment pill
The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
